Featuring perspectives from Dr Petros Grivas, Dr Vadim S Koshkin, Dr Kriti Mittal, Dr Mamta Parikh and Dr Scott T Tagawa, including the following topics:

First-Line Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Enfortumab Vedotin/Pembrolizumab

• Case: A man in his late 80s with recurrent unresectable locally advanced UBC receives first-line enfortumab vedotin and pembrolizumab — Dr Parikh (0:00)
• Case: A woman in her mid 60s with newly diagnosed mUBC attains an excellent response with first-line enfortumab vedotin and pembrolizumab — Dr Mittal (12:14)

Other Approaches to First-Line Treatment of mUBC — Nivolumab/Chemotherapy

• Case: A man in his mid 70s with multiregimen-recurrent mUBC attains a complete response to enfortumab vedotin monotherapy — Dr Koshkin (25:22)
• Case: A man in his mid 70s with muscle-invasive bladder cancer with 50% squamous histology receives adjuvant nivolumab — Dr Mittal (35:07)
• Comparing new first-line treatments for previously untreated unresectable or metastatic UBC: Brentuximab vedotin/pembrolizumab and nivolumab/chemotherapy (43:18)

Integrating Enfortumab Vedotin Monotherapy into the Treatment of mUBC

• Case: A man in his late 70s with recurrent mUBC and disease progression after treatment on 2 clinical trials experiences a complete response with enfortumab vedotin monotherapy — Dr Parikh (48:15)
• Monitoring and management of enfortumab vedotin-associated dermatologic and neurologic side effects (50:53)
• Case: A woman in her early 60s with multiregimen-refractory mUBC — Dr Mittal (59:26)

• Case: A man in his early 60s with relapsed/refractory mUBC with HER2 amplification experiences intolerable toxicities with enfortumab vedotin — Dr Parikh (1:43:25)
• Case: A woman in her mid 70s with relapsed/refractory HER2-low mUBC — Dr Koshkin (1:56:36)